X4 Pharmaceuticals, Inc. XFOR

US Biotechnology

$3.26 ▼ -2.10% ($-0.07)

Open $3.29

Prev Close $3.33

Day Range $3.22 – $3.36

52W Range $2.43 – $4.83

Market Cap $332.14M

Beta 0.61

EPS (TTM) $-0.71

📋 Company Profile

Industry	Biotechnology
Country	US
Exchange	NASDAQ NMS - GLOBAL MARKET
Currency	USD
IPO Date	2017-11-16
Shares Out.	99,150,000
Website	x4pharma.com/ ↗
Phone	18668207754
Employees	45
Revenue	$2.9M
Gross Profit	$2.4M
Net Income	-$20.2M
Free Cash Flow	-$76.1M
Total Assets	$231.8M
Total Liabilities	$92.9M
Equity	$138.9M

About X4 Pharmaceuticals, Inc.

X4 Pharmaceuticals Inc is a biopharmaceutical company developing and commercializing novel therapeutics for the treatment of rare hematology diseases. The Company's clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It can increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.

X4 Pharmaceuticals, Inc. is a publicly traded company under the ticker symbol XFOR on the NASDAQ NMS - GLOBAL MARKET, operating in the Biotechnology industry. Quotes and metrics shown here are sourced from public market data and refreshed regularly.